a Introduction The ABSORB bioresorbable vascular scaffold (BVS) is associated with greater neointimal proliferation and thrombotic rate than metal stent. The role of inflammatory biomarkers on neointimal proliferation has not been studied in the setting of BVS implantation.
Introduction The ABSORB bioresorbable vascular scaffold (BVS) is associated with greater neointimal proliferation and thrombotic rate than metal stent. The role of inflammatory biomarkers on neointimal proliferation has not been studied in the setting of BVS implantation.
Patients and methods Thirty patients had arterial blood sampling before elective percutaneous coronary intervention with the ABSORB BVS and at 9-months followup. Plasma levels of interleukin-6, soluble CD40 ligand, monocyte chemotactic protein-1 and C-reactive protein were measured using enzyme-linked immunosorbent assay. Baseline and follow-up levels were compared for each biomarker. Optical frequency domain imaging was performed at follow-up and the neointimal burden was calculated as the ratio of neointimal area to scaffold area. The levels of inflammatory mediators were correlated with the neointimal burden.
Results There was no significant increase in the levels of biomarkers from baseline to follow-up. Median C-reactive protein levels changed from 1. The average neointimal burden in the cohort was 18 ± 6%. Baseline, follow-up and change in plasma levels of inflammatory markers between these two time points did not correlate with the neointimal burden.
Conclusion Elective percutaneous coronary intervention with the ABSORB BVS does not provoke a chronic inflammatory response. The degree of neointimal proliferation after elective implantation of the ABSORB BVS is independent of the pre-existing inflammatory environment. Coron Artery Dis 30:183-187 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Randomized controlled trials and registry data have shown that the ABSORB bioresorbable vascular scaffold (BVS) is associated with a higher rate of thrombosis and late luminal loss [1, 2] . Some of the contributory factors such as malapposition, late scaffold dismantling and underdeployment [3] have been identified but the influence of inflammation on the restenotic/thrombotic response has not been investigated. It is known that metal stents can induce chronic inflammation causing a potent neointimal response and a high rate of in-stent restenosis (ISR) [4] . Histopathological analyses of restenotic tissue have shown a higher preponderance of inflammatory cells and fibrinoid tissue indicating an incomplete healing response [5] . Biological factors responsible for this phenomenon include hypersensitivity reactions either to the metallic platform or to the polymer jacket and resistance to the antiproliferative drug [6, 7] . In contrast, healthy porcine coronary arteries treated with the ABSORB BVS have shown a relatively benign vessel response compared with first generation drug-eluting stents (DESs) [8] . Whether the lower levels of inflammation seen in these preclinical studies can be extrapolated to diseased human arteries is unknown.
The inflammatory response after percutaneous coronary intervention (PCI) is influenced not only by the vascular injury induced by the procedure but also by the preexisting inflammatory environment. In clinical settings, the baseline inflammatory status has been assessed with a wide variety of markers including C-reactive protein, interleukin-6 (IL-6), monocyte chemotactic protein-1 and soluble CD40 ligand (sCD40L). Patients with high preinterventional inflammatory activation seem to be at a greater risk of ISR [9] [10] [11] [12] [13] . So far no study has investigated the effect of preprocedural inflammatory state on subsequent neointimal growth after treatment with BVS.
Patients and methods

Study design and population
The study population consisted of 30 patients who had elective PCI with the ABSORB BVS for bifurcation disease. The inclusion criteria were the presence of 'false' bifurcation disease (Medina type 1,1,0 or 1,0,0 or 0,1,0) with more than 70% stenosis in the main vessel and a side branch diameter above 2 mm on visual assessment. Major exclusion criteria were acute presentation either with unstable angina or acute coronary syndrome, bifurcation disease involving the left main stem and chronic total occlusion of either the main vessel or side branch. All patients were recruited from a single centre between February 2015 and July 2016. As part of the research protocol, all patients had peripheral arterial blood sampling before PCI (baseline) and 9 months after the procedure (follow-up). Informed consent was obtained from all participants. Patients underwent optical frequency domain imaging (OFDI) post-BVS implantation and at follow-up. The clinical investigational plan, consent form and all amendments to these study documents were reviewed and approved by the South East Coast (Brighton and Sussex) Research Ethics Committee.
Biochemical analysis
Two sets of 10 ml blood samples were taken from the arterial sheath from each patient, first before scaffold implantation and again at 9 months after implantation. Blood was collected in EDTA-tubes (BD Vacutainers, purple cap; Becton Dickinson, Franklin Lakes, New Jersey, USA) and centrifuged at 1500 rpm for 10 min. The resulting plasma was collected and aliquoted into five samples of 500 µl each. All samples were processed and frozen within 3 h of collection. Samples were stored at − 80°C at the local hospital. These were transferred on dry ice to the laboratory for analysis. Plasma levels of inflammatory markers were measured by enzyme-linked immunosorbent assay using commercially available assay kits from DRG Diagnostics (Marburg, Germany; high-sensitivity C-reactive protein) and Bio-Techne (Minneapolis, Minnesota, USA; high-sensitivity IL-6, sCD40L and monocyte chemotactic protein-1).
Optical frequency domain imaging acquisition and analysis
OFDI imaging was performed using the FastView catheter R and the Lunawave coronary imaging console (Terumo Corporation, Tokyo, Japan). The OFDI catheter was carefully advanced over a guidewire beyond the target area. While contrast was continuously injected at a rate of 4 ml/s, OFDI images of the main vessel were acquired at a rate of 160 frames/s with a pullback speed of 20 mm/s.
OFDI analysis was performed offline using software provided by Terumo (Terumo Corporation). Quantitative measurements were performed at 1-mm intervals starting from the first image where at the scaffold was visible in at least three quadrants. In each slice, the abluminal scaffold area, total strut area and luminal area were measured. The neointimal burden was calculated as the percentage of the neointimal area to scaffold area as shown below [14] .
Neointimal burden¼ Neointimal area=scaffold area ð Þ Â 100 % :
Statistical analysis
Continuous variables are presented as mean ( SD) if normally distributed and median (interquartile range) when not normally distributed. Discrete data are presented as n (%). Test for normality was performed with the Shapiro-Wilk test. The distribution of inflammatory biomarker levels was non-normal and thus a comparison between baseline and follow-up levels was made using the Wilcoxon signed-rank test. Correlation between levels of inflammatory markers and the neointimal burden was made using the Spearman rank correlation coefficient. The level of statistical significance for hypothesis testing was P less than 0.05. All statistical calculations were performed using SPSS software (version 24; SPSS Inc., Chicago, Illinois, USA).
Results
Population characteristics Table 1 summarizes the patient and procedural characteristics at baseline. Twenty-three (77%) patients were male and the mean age was 62.8 years. All patients had stable coronary disease. None of the patients had a pre-existing inflammatory condition, renal or liver dysfunction. Procedural success was 100%. Mean follow-up period was 313 50 days. 
Imaging results at 9 months
There were no cases of either binary restenosis or thrombosis. All stented vessels and side branches were widely patent. The vascular response was fairly benign with an average neointimal burden of 18 6%. Mean inscaffold luminal diameter reduced from 2.89 0.35 to 2.70 0.39 mm (P = 0.0001).
The relationship between baseline and follow-up levels of inflammatory markers Table 2 compares the baseline and follow-up levels of each marker. None of the inflammatory markers showed a significant change in plasma level from baseline to follow-up.
The relationship between inflammatory markers and neointimal growth Table 3 summarizes the Spearman correlation between each marker and neointimal burden on follow-up OFDI.
We investigated levels at baseline, follow-up as well as the difference in levels between the two time points (Δ = follow-up levels − baseline levels). None of these parameters showed a significant association with the degree of neointimal growth at 9 months. It is worth mentioning one case where the patient had a significantly elevated sCD40L baseline level of 2421 pg/ml compared with the cohort median of 108 pg/ml. The patient's clinical and procedural characteristics were not significantly different from those in the group. Interestingly, there was a large amount of intracoronary thrombus evident on OFDI shortly after BVS deployment despite preprocedural treatment with DAPT ( Fig. 1) . By 9 months, the sCD40L level had reduced to 71 pg/ml. OFDI imaging at that time point did not show persistent thrombus or an excessive hyperplastic response (neointimal burden: 19%).
Discussion
Our study is the first to look at the influence of serum markers of inflammation in the context of PCI with the ABSORB BVS. The findings of our study can be summarized as: (i) BVS implantation in an elective setting does not cause persistent inflammation at 9 months as assessed by serum inflammatory markers; and (ii) the extent of neointimal tissue growth is independent of the inflammatory status at baseline and follow-up.
Bioresorbable vascular scaffold implantation in an elective setting is not associated with persistent inflammation at 9 months
Elective stenting initiates a complex cascade of physiological processes aimed at repairing the vessel. This local inflammatory process can be assessed using indices in the peripheral blood [15, 16] . Persistence of the inflammatory process after stent implantation changes the physiological reparative response to a pathological one. The underlying inflammatory environment is a strong predictor of ISR The changes between baseline and follow-up inflammatory markers levels were analysed by the Wilcoxon signed-rank test and the P value is reported. CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; MCP-1, monocyte chemotactic protein-1; sCD40L, soluble CD40 ligand. Optical frequency domain imaging image demonstrating multiple thrombi after bioresorbable vascular scaffold deployment. The patient had a significantly elevated baseline level of soluble CD40 ligand (2421 pg/ml) compared with the cohort median (108 pg/ml).
Inflammation after ABSORB BVS implantation
and stent thrombosis [17] . In the clinical setting, this chronic inflammatory response causes elevated levels of systemic biomarkers, which can be used as a surrogate marker for the underlying inflammatory status [18] .
On the basis of our study, the polymer and its degradation products do not seem to evoke a systemic inflammatory response at medium term after the ABSORB BVS is implanted in an elective setting. Despite extensive published literature on the ABSORB BVS, the inflammatory response in humans is still poorly understood. Chronic lowgrade inflammation induced by either the polymer or its degradation products has been postulated as one possible cause for the high thrombotic rate [3] . However, both poly (L-lactic acid) [19] and poly(D,L-lactic acid) [20] polymers have been used in the human coronary artery without major safety concerns. The final degradation products of the scaffold are D-lactic acid and L-lactic acid both of which naturally occur in the body. The amount of these products dispersed into the body as a result of scaffold disintegration is far below the normal reference levels in the body [21] . It does not appear that the intermediate oligomers elicit a toxic tissue response either, at least in animal studies. In a swine model implanted with BVS, the percentage of struts with giant cells and granulomas decreases progressively over 24 months [8] and in a swine model poly (D,L-lactic acid)-based BRS induce inflammation with a peak at 6 months and decreasing thereafter [22] .
However, inflammation may play a more prominent role in the more advanced stages of bioresorption. While the vascular response in porcine arteries is relatively benign, the inflammation score is at its peak between 12 and 18 months [23] . This timing coincides with the highest rate of mass loss and formation of degradation products.
Our findings are supported by the comparable incidence of binary restenosis at 1 year between BVS and Xience DES seen in ABSORB China [24] and Japan [25] .
The extent of neointimal tissue growth at 9 months is independent of the inflammatory status at baseline and follow-up
The biologic response to the ABSORB BVS is probably closer to that following PCI with DES than with bare metal stent (BMS). While the predictive role of preprocedural inflammation in the development of BMS restenosis is well established, its significance in patients receiving DES is less clear. Several studies have failed to show an association between neointimal hyperplasia and either preinterventional or postinterventional biomarker levels in DES restenosis [10, 26, 27] . The release of potent antiproliferative agents in DES alters the biological response to vessel injury. Limus analogues have antiinflammatory properties in addition to their inhibitory effect on the cell cycle. In particular, everolimus has been found to inhibit neutrophil activation, mitigate proinflammatory tumour necrosis factor-related pathways and promote the release on the anti-inflammatory cytokines [28, 29] . In addition, inhibition of the mTOR pathway in platelets prevents platelet activation and aggregation. This suppressive effect on inflammation may explain the lack of correlation we observed between baseline inflammatory status and neointimal growth.
We also did not observe any association between followup levels of inflammatory markers and intensity of neointimal response. It is possible that the excessive hyperplastic response seen in restenosis is affected through mechanisms other than inflammation. In contrast to restenosis in BMS, a heterogeneous tissue composition is observed in most cases of BVS restenosis. In particular, restenotic lesions that occur more than 6 months after implantation show signs suggestive of neoatherosclerosis [30] . Such systemic processes may play a more important role than locally induced inflammation in the pathology of BVS restenosis.
Finally, the case of very high preprocedural sCD40L level deserves special mention. sCD40L not only plays a role in inflammation but also in platelet activation after plaque rupture, as the CD40/CD40L complex increases the expression of tissue factor while thrombomodulin expression is reduced thus creating a procoagulant state [31] . Studies using IL-6 and other markers as surrogates of inflammation have compared levels of sCD40L in both healthy individuals and cardiac patients [32] . sCD40L levels appear to be more a marker of platelet activation than inflammation in patients with coronary artery disease. The large thrombotic burden evident on OFDI in conjunction with the very high preprocedural sCD40L suggests that pre-existing thrombotic propensity may be an important factor in the development of scaffold thrombosis.
The identification of such individuals may be a key to the challenging issue of in-scaffold thrombosis. The choice of appropriate biomarkers of platelet activation for risk stratification warrants further investigation.
Limitations
The main limitation of our study is its small sample size. This was a single centre study and our data may not be applicable to all patients. Baseline inflammatory marker levels were low in our group and our results may not be applicable in the higher inflammatory environment of acute coronary syndromes. None of the patients in our cohort had extensive neointimal proliferation on OFDI or angiographic ISR. It is possible that inflammatory markers only show discriminatory power in patients with a large neointimal burden. Furthermore, our study design was limited to 9 months with an OFDI endpoint. Thus, we cannot comment on the role of inflammation in the advanced stages of the resorption process. Very late ISR and thrombosis may progress through different pathological mechanisms that would not have been identified in our study.
Conclusion
Elective implantation of the ABSORB BVS does not elicit persistent inflammation within the coronary artery at medium term. The neointimal response after scaffold implantation is independent of the underlying inflammatory environment before scaffold implantation and at follow-up. Thrombotic predisposition at baseline may play a part in the development of subsequent scaffold thrombosis. Future studies are needed to investigate this observation.
